Home / Health / Wegovy Mega-Dose Jab Approved in UK
Wegovy Mega-Dose Jab Approved in UK
14 Apr
Summary
- A new single-injection Wegovy pen delivers 7.2mg of semaglutide.
- Clinical trials show up to 20.7% average weight loss with the higher dose.
- The MHRA approved the new triple-dose pen for UK rollout in 4-6 weeks.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new Wegovy pen in the UK, allowing users to administer the maximum maintenance dose of 7.2mg of semaglutide via a single weekly injection. This development eliminates the need for patients to inject three separate 2.4mg doses, simplifying the process for weight loss and weight maintenance.
The new single-dose device, manufactured by Novo Nordisk, is set to be rolled out in the UK within the next four to six weeks. This practical change aims to make weight management more accessible. The MHRA's approval follows the STEP UP clinical trial, which revealed that adults using the 7.2mg dose, alongside diet and exercise, achieved an average weight loss of up to 20.7% over 72 weeks.
Despite the advancements, some obesity experts urge caution due to the significant dose increase and potential side effects, such as gastrointestinal issues. While the new device will require a NICE review for NHS cost-effectiveness, it will be available on private prescriptions. The MHRA continues to monitor Wegovy's safety and encourages reporting of any suspected side effects.
